Literature DB >> 24936322

Breast cancer local recurrence under the form of inflammatory carcinoma, treated with concurrent radiation and chemotherapy, a case report.

Isabel Reis1, Helena Pereira1, Isabel Azevedo1, João Conde1, Isabel Bravo2, Rogéria Craveiro2, Deolinda Pereira3.   

Abstract

The authors present a case report of a patient with breast cancer diagnosed in 2005, treated with conservative surgery, adjuvant chemotherapy and radiotherapy, followed by hormonal therapy until 2010, who relapsed under the form of inflammatory breast cancer in 2011. After tumor progression detected during primary systemic therapy, a concurrent radiation and radiosensitizing chemotherapy were proposed. There was a significant clinical response to this treatment, enabling curative chance with total mastectomy. The histological examination of the breast and regional lymph nodes revealed a complete response, since there was no evidence of residual tumor. There are few reports concerning concurrent radiotherapy and chemotherapy in locally advanced breast cancer, but it could be a suitable "loco regional rescue therapy" to further reduce tumor progression and allow curative surgery. Study of this treatment strategy in randomized clinical trials is warranted.

Entities:  

Keywords:  Concurrent radiation and chemotherapy; Locally advanced breast cancer; Reirradiation

Year:  2013        PMID: 24936322      PMCID: PMC4056521          DOI: 10.1016/j.rpor.2013.09.004

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  26 in total

1.  Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials.

Authors:  Johnny Kao; Suzanne D Conzen; Nora T Jaskowiak; David H Song; Wendy Recant; Rachana Singh; Gregory A Masters; Gini F Fleming; Ruth Heimann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

2.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Authors:  Joseph Ragaz; Ivo A Olivotto; John J Spinelli; Norman Phillips; Stewart M Jackson; Kenneth S Wilson; Margaret A Knowling; Christopher M L Coppin; Lorna Weir; Karen Gelmon; Nhu Le; Ralph Durand; Andrew J Coldman; Mohamed Manji
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

3.  Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.

Authors:  Harold J Burstein; Jennifer R Bellon; Sharon Galper; Hsiao-Ming Lu; Irene Kuter; Alphonse G Taghian; Julia Wong; Rebecca Gelman; Craig A Bunnell; Leroy M Parker; Judy E Garber; Eric P Winer; Jay R Harris; Simon N Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-21       Impact factor: 7.038

4.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

Authors:  Ian C Smith; Steven D Heys; Andrew W Hutcheon; Iain D Miller; Simon Payne; Fiona J Gilbert; Antoinne K Ah-See; Oleg Eremin; Leslie G Walker; Tarun K Sarkar; S Peter Eggleton; Keith N Ogston
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

5.  Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial.

Authors:  Silvia C Formenti; Matthew Volm; Kristin A Skinner; Darcy Spicer; Deidre Cohen; Edith Perez; Anna C Bettini; Susan Groshen; Conway Gee; Barbara Florentine; Michael Press; Peter Danenberg; Franco Muggia
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

6.  Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies.

Authors:  Hanne M Nielsen; Marie Overgaard; Cai Grau; Anni R Jensen; Jens Overgaard
Journal:  J Clin Oncol       Date:  2006-04-17       Impact factor: 44.544

7.  Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.

Authors:  A Bapsi Chakravarthy; Mark C Kelley; Bernadette McLaren; Cristina I Truica; Dean Billheimer; Ingrid A Mayer; Ana M Grau; David H Johnson; Jean F Simpson; R Daniel Beauchamp; Catherine Jones; Jennifer A Pietenpol
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

8.  Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer.

Authors:  V F Semiglazov; E E Topuzov; J L Bavli; V M Moiseyenko; O A Ivanova; I K Seleznev; A A Orlov; N Y Barash; O M Golubeva; O F Chepic
Journal:  Ann Oncol       Date:  1994-09       Impact factor: 32.976

Review 9.  Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.

Authors:  Sylvie Delanian; Jean-Louis Lefaix
Journal:  Semin Radiat Oncol       Date:  2007-04       Impact factor: 5.934

Review 10.  Approach to inflammatory breast cancer.

Authors:  Andrea Molckovsky; Barbara Fitzgerald; Orit Freedman; Ruth Heisey; Mark Clemons
Journal:  Can Fam Physician       Date:  2009-01       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.